SYS-CON MEDIA Authors: Kevin Benedict, Jason Bloomberg, David H Deans, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Misonix, Inc. Enhances its Web Presence with the Unveiling of its New Website

FARMINGDALE, N.Y., Jan. 31, 2014 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, launched its new corporate website on January 27, 2014.

The newly redesigned website, www.misonix.com, has been streamlined to reflect the Misonix brand identity and features its portfolio of products, including the BoneScalpel™, SonaStar™, and SonicOne O.R.™ Complete product listings and support materials, as well as easy access to investor and clinical information, will be available in a streamlined and intuitive format. "This new website is an important step for the company as we commit to building tools to better communicate with our customers and various stakeholders. This platform will continue to be updated with new products, information, and functionality as they become available," stated Michael A. McManus, Jr., President and Chief Executive Officer of Misonix.

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Company Contact:​

Investor Contacts:

Richard Zaremba

Robert Blum, Joe Dorame, Joe Diaz

Misonix, Inc. ​​

Lytham Partners, LLC

631-694-9555

602-889-9700

[email protected]

[email protected]

www.misonix.com 

www.lythampartners.com

SOURCE Misonix, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.